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Abstract: In chronic kidney disease (CKD), impaired kidney function results in accumulation of uremic
toxins, which exert deleterious biological effects and contribute to inflammation and cardiovascular
morbidity and mortality. Protein-bound uremic toxins (PBUTs), such as p-cresyl sulfate, indoxyl
sulfate and indole-3-acetic acid, originate from phenolic and indolic compounds, which are end
products of gut bacterial metabolization of aromatic amino acids (AAA). This study investigates
gut microbial composition at different CKD stages by isolating, identifying and quantifying PBUT
precursor-generating bacteria. Fecal DNA extracts from 14 controls and 138 CKD patients were
used to quantify total bacterial number and 11 bacterial taxa with qPCR. Moreover, isolated bacteria
from CKD 1 and CKD 5 fecal samples were cultured in broth medium supplemented with AAA
under aerobic and anaerobic conditions, and classified as PBUT precursor-generators based on their
generation capacity of phenolic and indolic compounds, measured with U(H)PLC. In total, 148
different fecal bacterial species were isolated, of which 92 were PBUT precursor-generators. These
bacterial species can be a potential target for reducing PBUT plasma levels in CKD. qPCR indicated
lower abundance of short chain fatty acid-generating bacteria, Bifidobacterium spp. and Streptococcus
spp., and higher Enterobacteriaceae and E. coli with impaired kidney function, confirming an altered
gut microbial composition in CKD.
Keywords: qPCR; bacterial culture; fecal bacteria; chronic kidney disease; protein-bound uremic
toxins; bacterial metabolization; aromatic amino acids; p-cresol; indole; indole-3-acetic acid; phenol
1. Introduction
In chronic kidney disease (CKD), impaired kidney function results in the accumulation of uremic
toxins [1–3], which exert deleterious biological effects and contribute to inflammation and cardiovascular
morbidity and mortality [4–8]. Well-known protein-bound uremic toxins (PBUTs), p-cresyl sulfate
(pCS), p-cresyl glucuronide (pCG), indoxyl sulfate (IxS) and indole-3-acetic acid (IAA) originate in
the colon, where aromatic amino acids (AAA) are metabolized by gut bacteria into phenolic (p-cresol
and phenol) and indolic compounds (indole and IAA) [9–12]. p-Cresol and indole are sulfated in the
colon mucosa and by the liver into pCS and IS, and a small part is glucuronidated into pCG [9,13,14],
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while IAA enters the circulation without further modifications [15–17]. These PBUTs reversibly bind to
plasma albumin [18]; however, only the free fraction can be removed by dialysis [19,20].
During recent years, there is increasing evidence that the gut bacterial composition is
altered in patients with CKD [21–30]. Generally, in CKD, increased growth of both aerobes and
anaerobes takes place in the small intestine [24,25], while in the colon the numbers of aerobic
bacteria (e.g., Enterobacteriaceae) are increased [23,30] and anaerobic bacteria (e.g., bifidobacteria) are
decreased [23,29,30]. The increased aerobic bacterial growth is a consequence of an elevated pH
resulting from the high ammonia levels in the gut in CKD [31]. Ammonia is a bacteria-derived
hydrolysis end product of urea, which accumulates in the circulation and enters the gut lumen via
the entero-hepatic cycle [31] and by diffusion through the disrupted intestinal epithelial barrier as is
typically seen in patients with CKD [32,33]. This leads to a uremic milieu in the gut lumen, altering the
gut microbial composition in favor of urease expressing bacteria in end stage kidney disease (ESKD)
patients [27]. However, in a recent study by our group [34], the generation of fecal PBUT precursor
metabolites by fecal bacteria did not alter with CKD progression nor compared to controls. This
suggests that the accumulation of PBUTs in plasma is mainly due to the impaired kidney function itself.
Nevertheless, minimizing the generation by gut bacteria of phenolic and indolic compounds in
the hope to subsequently reduce plasma PBUT levels remains an important goal due to the absence of
other adequate therapies to reduce the plasma levels of PBUTs in patients with CKD. It is known that
certain bacterial isolates are capable to generate PBUT precursors in an in vitro setting [9,35–40], but
the generation capacity of fecal bacteria isolated from patients with CKD has not yet been investigated.
Numerous studies in patients with CKD already addressed the idea of applying pro-, pre- and
synbiotics [30,41–46] to increase saccharolytic and decrease proteolytic bacteria. Thus far, only one
specific PBUT has been targeted [47]. In addition, it has been shown that dietary intake is the most
important determinant of the fecal metabolome in CKD, next to the loss of kidney function [13],
suggesting that diet could also play an important role in altering the gut bacterial composition in a
favorable way. Intake of low-protein diets lowers the serum levels of IxS and the generation of various
phenolic and indolic metabolites in healthy humans and mice [48].
In this study, bacterial isolates obtained from fecal samples from patients with CKD stage 1 and
stage 5 were taxonomically characterized and metabolically classified as PBUT precursor-generating
bacteria based on their capacity to assimilate AAA into phenolic (p-cresol and phenol) and/or indolic
(indole and IAA) compounds. In addition, the abundance of specific fecal PBUT precursor-generating
bacteria in the different stages of CKD and in controls was investigated.
2. Results
2.1. Culture Media to Isolate Protein-Bound Uremic Toxin Precursor-Generating Bacteria from Fecal Samples
To isolate PBUT precursor-generating bacteria, an appropriate culture medium had to be
selected. Therefore, seven different media were compared based on the cultivation of a bacterial
test panel consisting of 12 known uremic toxin precursor-generating bacterial species (Figure S1),
and the cultivation of fecal bacteria from whole fecal samples (Table S1). Besides the commercially
available Schaedler medium (SCH, Becton Dickinson, Erembodegem, Belgium), the yeast casitone
fatty acid glucose (YCFAG) medium [37,49] was used as the basis for another six media, of which
specific components were omitted separately, to check their importance for the cultivation of UT
precursor-generating bacteria. Moreover, the effect of the supplementation of AAA and of a fecal
suspension from healthy volunteers (FS) was investigated.
All bacterial species from the test panel were culturable with the 24 YCFAG media combinations,
except for Bifidobacterium sp. and Lactobacillus sp., which only grew when AAA and FS were added to
the complete YCFAG (YCFAG ∆0), YCFAG without vitamins (YCFAG ∆V) or YCFAG without short
chain fatty acids (YCFAG ∆S). For the SCH medium, addition of AAA was detrimental for the growth
of most tested bacterial species, except B. longum, E. coli, L. paracasei, and S. epidermidis. SCH medium,
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with and without the supplementation of FS, resulted in the growth of all species of the test panel
(Figure S1). Based on these results, the five medium formulations that supported growth of all bacterial
species (i.e., YCFAG ∆0 +AAA +FS, YCFAG ∆V +AAA +FS, YCFAG ∆S +AAA +FS, SCH and SCH
+ FS) were used further to culture bacteria from fecal samples. Table S1 provides an overview of all
microorganisms that could be cultured on these five media. Most anaerobic and aerobic bacteria were
isolated from YCFAG ∆0 +AAA +FS and from SCH, and these media were further used to isolate
PBUT precursor-generating bacteria from fecal samples of patients with CKD.
2.2. Isolation and Identification of Protein-Bound Uremic Toxin-Generating Bacteria from Fecal CKD Samples
Figure S2 illustrates an overview of the isolation of PBUT precursor-generating bacteria. In total,
148 different bacterial species were isolated from CKD 1 (n = 6) and CKD 5 (n = 6) fecal samples to
cover fecal bacteria representative for both early and late stage of CKD. Of these, 99 species could be
identified by means of MALDI-TOF (Bruker, Mannheim, Germany) and 92 were considered as PBUT
precursor-generating bacteria when, for at least one of the precursor metabolites (i.e., p-cresol, phenol,
indole or IAA), the levels were above the limit of detection (LOD) as assessed by U(H)PLC. Table 1
lists all isolated bacterial species with their generation capacity of PBUT precursors under aerobic and
anaerobic conditions. Generally observed, p-cresol and phenol were mainly generated under anaerobic
conditions, while indole and IAA could be generated under both aerobic and anaerobic conditions.
Phenolic compounds and IAA were predominantly generated by bacterial species belonging to the
Actinomycetaceae, Bacteroidaceae, Clostridiaceae, Enterococcaceae, Lachnospiraceae, Staphylococcaceae and
Tannerellaceae, while indolic compounds were mainly generated by the Bifidobacteriaceae, Coriobacteriaceae,
Enterobacteriaceae, Propionibacteriaceae and Rikenellaceae. In addition, Bacteroides uniformis, Odoribacter
splanchnicus and Oscillibacter sp. are the only bacterial species capable of generating all four PBUT
precursor metabolites under anaerobic conditions.
Table 1. Protein-bound uremic toxin precursor-generating capacity of bacteria isolated from fecal
samples of patients with chronic kidney disease (CKD).
Bacterial Species CKD 1 (n = 6) CKD 5 (n = 6)
Neg pC Phe Ind IAA Neg pC Phe Ind IAA
ACTINOBACTERIA
Actinomycetaceae
Actinomyces sp. O4 O4
Bifidobacteriaceae
Bifidobacterium adolescentis N9 N1




Bifidobacterium dentium N1 N1






Collinsella aerofaciens O1 N4
Corynebacteriaceae
Corynebacterium amycolatum O1 O1










Cutibacterium acnes N2 N2 N1 N1
Propionibacterium freudenreichii N1
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Table 1. Cont.
Bacterial Species CKD 1 (n = 6) CKD 5 (n = 6)
Neg pC Phe Ind IAA Neg pC Phe Ind IAA
BACTEROIDETES
Bacteroidaceae
Bacteroides sp. N1 N1 N1 N1 N1
Bacteroides caccae N1 N1 N1 N1 N1 N1
Bacteroides cellulosilyticus N1 N1
Bacteroides coprocola N1 N1
Bacteroides eggerthii N1 N1 N1 N1 N1 N1
Bacteroides faecis N1 N1
Bacteroides finegoldii N1 N1 N1
Bacteroides fragilis N1 N1 N1 O1 O1 O1
Bacteroides intestinalis NC
Bacteroides massiliensis N1 N1
Bacteroides ovatus N1 N1 N1 N1 N1
Bacteroides pyogenes N1 N1
Bacteroides salyersiae N1 N1
Bacteroides stercoris NC
Bacteroides thetaiotaomicron N2 N2
Bacteroides uniformis N1 N1 N1 N1 N2 N2 N4 N3
Bacteroides vulgatus N2 N1 N2 N1 N1
Odoribacteriaceae
Odoribacter splanchnicus N3 N3 N3 N3
Prevotellaceae
Prevotella copri N1 N1
Rikenellaceae
Alistipes putredinis N1 N1
Alistipes shahii N2 N2
Tannerellaceae
Parabacteroides distasonis N2 N2
Parabacteroides goldsteinii N1 N1
Parabacteroides johnsonii N1 N1
Parabacteroides merdae N1 N2 N3
FUSOBACTERIA
Fusobacteriaceae










Bacillus subtilis O1 O1
Clostridiaceae
Clostridium perfringens N1 N1
Clostridium tertium O1 O1
Enterococcaceae
Enterococcus avium O1 O1
Enterococcus casseliflavus O1 O1 O1
Enterococcus durans d O2
Enterococcus faecalis d O2 O2




Erysipelatoclostridium ramosum c N2
Lachnospiraceae
Lachnoclostridium scindens N1 N1
Lachnoclostridium symbiosum c N1 N1 N1
Lactobacillaceae
Lactobacillus buchneri NC
Lactobacillus delbrueckii c N1
Lactobacillus paracasei NC NC
Lactobacillus rhamnosus O1/N1 O1/N1
Lactobacillus ruminis NC
Lactobacillus sakei NC
Pediococcus acidilactici c O1 O1
Oscillospiraceae
Oscillibacter sp. N1 N1 N1 N1
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Table 1. Cont.
Bacterial Species CKD 1 (n = 6) CKD 5 (n = 6)




Staphylococcus capitis N1 N1
Staphylococcus epidermidis N1 N1






Streptococcus gordonii O1 O1
Streptococcus lutetiensis O1/N2
















Bilophila wadsworthia N1 N1
Enterobacteriaceae




Escherichia coli * O7/N1 O7/N1 O15/N4 O15/N4
Klebsiella variicola c O1 O1
Pseudomonadaceae







MB 208_49 N1 N1 N1 N1
MB 210_6 N1
MB 210_38 N1 N1
MB 242_16 N1
MB 256_36 N1
MB 256_39 N1 N1
MB 256_61 N1 N1 N1
MB 263_32 N1
MB 275_15 N1 N1
MB 275_16 N1
MB 300_21 N1 N1
MB 314_01 O1 O1
Bacterial taxonomy according to Uniprot [50]; a: species not distinguishable with MALDI-TOF; b: species not
distinguishable with 16S rRNA gene sequencing; c: species with generation of unknown peak 26 on HPLC; d:
species with generation of an unknown peak 9 on HPLC; ◦: no identification after MALDI-TOF and/or 16S rRNA
gene sequencing; *: not distinguishable with Shigella spp. with MALDI-TOF; Neg.: No in vitro PBUT precursor
generation capacity; pC: p-cresol; Phe: phenol; Ind: indole; IAA: indole-3-acetic acid; O (oxygen): in vitro PBUT
precursor generation capacity under aerobic conditions (37 ◦C for 2 days); N (nitrogen): in vitro PBUT precursor
generation capacity under anaerobic conditions (37 ◦C for 6 days); x (in Ox/Nx): Number of isolates tested for
uremic toxin precursor generation; NC: could not be further cultured in broth to check the generation capacity of
PBUT precursors.
2.3. Quantification of Fecal Bacterial Species in Different Stages Of CKD
Quantitative PCR (qPCR) analysis was assessed in different stages of CKD and in controls for
11 bacterial taxa, and the total number of 16S rRNA gene copies with a universal bacterial qPCR
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(Figure 1). Prior to statistical analysis, one CKD 1 sample was excluded due to the absence of qPCR
signal for each of the performed assays (LOD > Concentration). The abundance of Bacteroides spp.,
Bifidobacterium spp., Faecalibacterium prausnitzii and Akkermansia muciniphila, as well as the total number
of bacterial 16S rRNA gene copies was comparable among the different stages of CKD and the control
group. In fecal samples from hemodialysis (HD) patients, a higher abundance of Streptococcus spp.
and Enterobacteriaceae was found compared to controls and early stages of CKD, and for Escherichia
coli compared to controls. Moreover, compared to HD patients, the abundance of Lactobacillus spp.
decreased in CKD stage 1–5 patients, and the abundance of Clostridioides difficile in all other CKD
stages and controls. Decreased levels of Roseburia spp. were observed in CKD 5 compared to controls,
CKD 1, HD and peritoneal dialysis (PD) patients. In addition, a lower abundance of Streptococcus
spp. was found in CKD 3 and CKD 4 compared to controls, while the opposite was found for E. coli,
i.e., an increase in CKD 3 compared to control. Finally, decrease in kidney function (ranging from
control to CKD 5) positively correlated with the abundance of Enterobacteriaceae (rs = 0.210), and E. coli
(rs = 0.286), while an inverse correlation was found with Streptococcus spp. (rs = −0.255), Butyricicoccus
spp. (rs = −0.326), F. prausnitzii (rs = −0.250), Roseburia spp. (rs = −0.342) and Bifidobacterium spp.
(rs = −0.303) (Figure 1; all p < 0.05). Similar results were obtained when correlating the abundance
of the bacterial taxa with estimated glomerular filtration rate (eGFR), except for Streptococcus spp.
(Table S2).
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patients), revealed no significant differences for the total bacterial 16S rRNA gene copies, the 
abundance of Bacteroides spp., Bifidobacterium spp., Butyricicoccus spp., F. prausnitzii, and Roseburia 
spp. (Figure 2). However, a higher abundance was found in the dialysis group compared to CKD for 
A. muciniphila, C. difficile, Enterobacteriaceae, Lactobacillus spp., and Streptococcus spp., and compared 
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Figure 1. Bacterial gene copi s per gram feces per chronic kidney diseas (CKD) stage: (a) Total bacterial
16S rRNA; (b) Clostridioides difficile; (c) Streptococcus spp.; (d) Bacteroides spp.; (e) Enterobacteriaceae; (f)
Escherichia coli; (g) Butyricicoccus spp.; (h) Faecalibacterium prausnitzii; (i) Roseburia spp.; (j) Akkermansia
muciniphila; (k) Bifidobacterium spp.; (l) Lactobacillus spp. *: p ≤ 0.05; **: p ≤ 0.001; rs: Spearman’s rank
test; gray square: correlation between respective bacteria versus CKD stages 1–5 and control.
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Comparison of the total bacterial number and the abundance of the 11 PBUT precursor-generating
bacterial taxa in the control, CKD (CKD stages 1 to 5) and dialysis groups (HD and PD patients),
revealed no significant differences for the total bacterial 16S rRNA gene copies, the abundance of
Bacteroides spp., Bifidobacterium spp., Butyricicoccus spp., F. prausnitzii, and Roseburia spp. (Figure 2).
However, a higher abundance was found in the dialysis group compared to CKD for A. muciniphila,
C. difficile, Enterobacteriaceae, Lactobacillus spp., and Streptococcus spp., and compared to controls for
C. difficile, Enterobacteriaceae, and E. coli. In addition, in CKD, the abundance of Streptocococcus spp.
decreased and of E. coli increased compared to the control group (Figure 2).
Int. J. Mol. Sci. 2020, 21, x 8 of 20 
 
 
Figure 2. Bacterial gene copies per gram feces for the control, CKD and dialysis group: (a) Total 
bacterial 16S rRNA; (b) Clostridioides difficile; (c) Streptococcus spp.; (d) Bacteroides spp.; (e) 
Enterobacteriaceae; (f) Escherichia coli; (g) Butyricicoccus spp.; (h) Faecalibacterium prausnitzii; (i) Roseburia 
spp.; (j) Akkermansia muciniphila; (k) Bifidobacterium spp.; (l) Lactobacillus spp.. *: p ≤ 0.05; **p ≤ 0.001. 
3. Discussion 
The gut microbiota is responsible for the generation of PBUTs [10,12,51], which accumulate in 
the blood circulation of patients with CKD [1–3]. At the moment, no effective therapies exist to reduce 
the plasma levels of these PBUTs. This is the first study to isolate and identify PBUT precursor-
generating bacteria from fecal samples from patients with CKD stage 1 and 5 patients. These results 
give us more insight regarding which bacteria are responsible for the metabolization of aromatic 
amino acids into phenolic (i.e., p-cresol and phenol) and indolic (i.e., indole and IAA) compounds. In 
addition, 11 PBUT precursor-generating bacterial taxa and the total number of bacteria were 
quantified, using qPCR, in patients with different stages of CKD and healthy controls. 
In total, 148 different bacterial species were isolated, of which 92 could be classified as PBUT 
precursor-generating bacteria. Moreover, to our knowledge, 51 of the isolated bacterial species were 
not previously described as generators of phenolic or indolic compounds. Fecal proteolytic bacterial 
species predominantly belong to the genera Bacteroides and Propionibacterium, and although with 
fewer representatives, also to the genera Bacillus, Clostridium, Staphylococcus and Streptococcus [52]. 
This is in line with the findings of the present study, in which the Bacteroidaceae, Clostridiaceae, 
Lachnospiraceae and Staphylococcaceae were the predominant generators of phenolic compounds in 
Figure 2. Bacterial gene copies per gram feces for the control, CKD and dialysis group: (a) Total bacterial
16S rRNA; (b) Clostridioides difficile; (c) Streptococcus spp.; (d) Ba teroides spp.; (e) Enterobacteriaceae; (f)
Escherichia coli; (g) Butyrici occus spp. (h) Faecaliba terium prausnitz i; (i) Roseburia spp.; (j) Akke mansia
muciniphila; (k) Bifidobacterium spp.; (l) Lactobacill s s . *: p ≤ 0.05; ** p ≤ 0.001.
3. Discus ion
The gut microbiota is responsible for the generation of PBUTs [10,12,51], hich accumulate in the
blood circulation of patients with CKD [1–3]. At the moment, no effective therapies exist to reduce the
plasma levels of these PBUTs. This is the first study to isolate and identify PBUT precursor-generating
bacteria from fecal samples from patients with CKD stage 1 and 5 patients. These results give us more
insight regarding which bacteria are responsible for the metabolization of aromatic amino acids into
phenolic (i.e., p-cresol and phenol) and indolic (i.e., indole and IAA) compounds. In addition, 11 PBUT
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precursor-generating bacterial taxa and the total number of bacteria were quantified, using qPCR, in
patients with different stages of CKD and healthy controls.
In total, 148 different bacterial species were isolated, of which 92 could be classified as PBUT
precursor-generating bacteria. Moreover, to our knowledge, 51 of the isolated bacterial species were
not previously described as generators of phenolic or indolic compounds. Fecal proteolytic bacterial
species predominantly belong to the genera Bacteroides and Propionibacterium, and although with fewer
representatives, also to the genera Bacillus, Clostridium, Staphylococcus and Streptococcus [52]. This is in
line with the findings of the present study, in which the Bacteroidaceae, Clostridiaceae, Lachnospiraceae
and Staphylococcaceae were the predominant generators of phenolic compounds in addition to IAA.
In the current study, these metabolites were also generated by bacterial species belonging to the
Actinomycetaceae, Tannerellacae, and Enterococcaceae, of which the latter family also was classified as a
phenolic compound-generating bacterial taxon [9]. Most fecal species with the capacity to generate
phenolic compounds belong to the genus Bacteroides, although species-to-species differences have been
reported [37,40,53]. These differences in the capacity to generate phenolic compounds by Bacteroides
spp. can be explained by the different compositions of the culture media used and thus by a different
substrate availability, which determines the metabolization pathway of gut bacteria (carbohydrate or
amino acid metabolization). This has already been reported for Bifidobacterium spp., which can switch
to the metabolization of amino acids in the absence of carbohydrates [36]. Because of the presence of
the tyrosine deaminase gene, Clostridiaceae and Enterobacteriaceae also have the property of converting
tyrosine into p-cresol, which were increased in ESKD patients [27]. However, in the present study, the
generation of p-cresol was only observed in bacterial species belonging to the Clostridiaceae. Moreover,
in the present study, bacterial species generating solely IAA belong to the Bacillaceae, Bifidobacteriaceae,
Brevibacteriaceae, Coriobacteriaceae, Corynebacteriaceae, Eggerthellaceae, Microbacteriaceae and Micrococcaceae,
while the other bacterial species mostly also produce indole and/or phenolic compounds. Conversion of
tryptophan into indole is performed by tryptophanase, an enzyme known to be expressed by (at least)
27 gut-associated genera [54]. Tryptophanase activity is also present in Clostridiaceae, Enterobacteriaceae
and Verrucomicrobia, which all have been reported to be elevated in ESKD patients [27]. Interestingly,
in this study, most of the Lactobacillus spp. generate none of the measured indolic and phenolic
compounds, but are potent generators of lactic acid and phenyl lactic acid [55,56]. In healthy conditions,
most abundant Lactobacillus spp. in the colon include L. casei, L. delbrueckii, L. plantarum, L. rhamnosus,
and L. ruminus [57], with the exception of L. plantarum, all of these were also isolated from the CKD
fecal samples in this study.
Based on the bacterial generation of phenolic and indolic compounds in vitro and the associations
between bacterial taxa with high pCS or high IxS serum levels in HD patients [58], 11 bacterial taxa
were selected to explore the abundance of these PBUT precursor-generators in different stages of
CKD. Altered gut microbial composition in CKD was observed by Vaziri et al., revealing a qualitative
difference of 190 operational taxonomic units between HD patients and controls [21]. A change in
the gut microbial composition is confirmed in our CKD cohort with changes in the abundance of
Butyricicoccus spp., C. difficile, Enterobacteriaceae, E. coli, Lactobacillus spp., Roseburia spp. and Streptococcus
spp. in the different stages of CKD and control. Moreover, a decline in kidney function was positively
associated with Enterobacteriaceae and E. coli, and negatively associated with Bifidobacterium spp.,
Butyricicoccus spp., F. prausnitzii, Roseburia spp. and Streptococcus spp.. However, the total number of
bacterial 16S rRNA gene copies was similar among all CKD stages and controls, in line with two other
studies comparing (non-)dialyzed ESKD patients with controls [29,59]. In a cultured-based approach to
estimate the total bacterial number, no significant differences were observed between HD and controls,
either [30], while in another culture study, a lower total number of bacteria were observed in CKD
and HD patients [23]. For Bacteroides spp., we found comparable amounts over the different CKD
stages and controls, which was also reported for B. fragilis in PD patients compared to controls [28].
Bacteroides is one of the most abundant bacterial genera in the gut of healthy adults and patients with
CKD [60]. Enrichment of aerobic bacteria in the colon of patients with CKD has been frequently
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reported [23,29,30,61,62], and was also confirmed in the present study (i.e., Enterobacteriaceae and E.
coli). However, this was not the case for all studies assessing the gut microbial composition in CKD. A
qPCR-based study found no differences in E. coli levels in PD patients and controls [63], while another
study found decreased E. coli levels in Chinese ESKD patients [29]. In addition, in this study, the
abundance of Streptococcus spp. decreased with impaired kidney function, and increased again under
dialysis therapy. Similar results were found in the study of Stadlbauer et al., with higher Streptococcus
spp. levels in HD [62] and type 2 diabetes mellitus CKD patients [64] compared to controls. Elevated
levels of Streptococcus spp. have been associated with a range of human infections [65].
The previously observed decrease of anaerobic bacteria in CKD [23,29] was also confirmed in the
present study with the decrease of Bifidobacterium spp. and the inverse correlation of Bifidobacterium
spp., Butyricicoccus spp., F. prausnitzii and Roseburia spp. with impaired kidney function. Bifidobacteria
and lactobacilli are commonly used probiotics, aiming at health-promoting effects to the host and
commensal gut microbiol homeostasis [66]. In our CKD cohort, the abundance of Lactobacillus spp.
was higher in HD patients compared to patients with CKD stages 1 to 5. In a previous sequence-based
comparison of the gut microbiota between patients with CKD stages 1 to 5 and non-CKD controls;
however, higher Lactobacillus spp. levels in CKD were found [60]. Another health-promoting bacterial
species is Akkermansia muciniphila, an essential propionate-generating and mucus-degrading species
that is beneficial through the production of energy from mucus degradation and as such supporting the
growth of butyrate-producing bacteria [60,67–69]. A sequencing study comparing CKD patients with
controls reported a strong negative correlation with CKD and a reduction of the genus Akkermansia,
of which the species A. muciniphila is the only human representative [60]. These findings are in
contrast to the present study with only a lower abundance of A. muciniphila in the CKD group
versus the dialysis group, and no inverse correlation with loss of kidney function. Other short
chain fatty acid (SCFA)-generating bacteria include Butyricicoccus spp., Faecalibacterium prausnitzii
and Roseburia spp., which predominantly colonize the colonic mucus layer and particularly generate
butyrate. Butyrate is beneficial for the health because it is an energy source for colonocytes and
it promotes cell differentiation, suppresses colonic inflammatory response, decreases luminal pH
and improves tight junction assembly [59,69–71]. Our results show that the three aforementioned
butyrate-producing taxa were inversely associated with impaired kidney function. This is consistent
with previous findings observing a decrease of butyrate-generating bacteria in ESKD patients compared
to controls [29,61,62,72] and depletion of microbial families possessing butyrate-forming enzymes
in ESKD patients [27]. However, in the study of Terpstra et al., the abundance of F. prausnitzii and
Roseburia spp. was comparable in ESKD patients and controls [59]. Finally, the pathogenic bacterium
C. difficile, which is related to severe antibiotic-associated diarrhea [73,74] and a well-known producer
of p-cresol [39,40], was elevated in the HD group of the present study. This increased abundance could
be explained by elevated antibiotic intake due to a higher infection rate in ESKD patients [74].
p-Cresol and indole originate from two independent metabolization pathways [9,17], which are
associated with a completely different gut microbial composition [58]. p-Cresol exerts various toxic
effects to biological functions [75–82]. This is in contrast to indole, which acts as an intercellular signal
molecule and contributes to the immune cell homeostasis and the host-microbe homeostasis at the
mucosal surface by promoting gene expression of gut epithelial cell junctions [17,35,83]. Of interest,
only a small fraction of tryptophan (~5%) in the gut is converted into indole, while the other fraction is
used in the kynurenine (~95%) and serotonin (~1-2%) pathway [17,54]. The beneficial properties of
indole imply that it is less desirable to reduce the generation of indole compared to the generation of
p-cresol, and in this context, the differentiated metabolization pathways of p-cresol and indole could
be considered as an advantage rather than a disadvantage. Pro-, pre- and synbiotics could play an
important role in minimizing the generation of only p-cresol and thus also of the plasma levels of pCS,
which is supported by numerous intervention studies in patients with CKD, showing only a reduction
of plasma pCS or IxS levels, but not of both toxins [30,41–46]. Of note, a decrease of aerobic bacteria,
generating mostly indolic compounds, could be beneficial to the gut microbial homeostasis considering
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the present aerobic overgrowth in CKD. These elevated levels of aerobes, shown to inhibit anaerobic
bacterial growth [23,30], could also negatively interfere with the activity of SCFA-generating bacteria.
As shown in the present study, phenolic compounds were mostly generated by bacterial species
from the phyla Bacteroidetes (i.e., Actinomycetaceae, Bacteroidaceae, Odoribacter splanchnicus, Prevotella
copri and Tannerellaceae) and Firmicutes (i.e., Clostridiaceae, Enterococcaceae, Lachnospiraceae, Oscillibacter
sp., Staphylococcaceae and Streptococcaceae). Quantification of Bacteroides spp., C. difficile and Streptococcus
spp. with qPCR revealed elevated levels of C. difficile and Streptococcus spp. in HD patients which
marks both taxa as potential targets to reduce p-cresol generation in patients with CKD. Bacteroides
spp. did not change in abundance in CKD versus controls, but could also be a target as these have
the capacity to generate phenolic compounds. To our knowledge, no interventions have so far been
assessed to reduce one of these bacterial taxa in patients with CKD or in healthy controls. Because
our results indicate that both Bifidobacterium spp. and Lactobacillus spp. are reduced with impaired
kidney function and although they are known to generate only IAA, these taxa may be potential
probiotics. In CKD, numerous studies have already addressed the impact of these bacterial species on
the reduction of plasma pCS and IxS levels and their gut-derived precursor metabolites [30,41–47,84,85].
Fecal p-cresol, fecal indole and plasma IxS could be reduced by a combination of antibiotic-resistant
lactic acid-generating bacteria (i.e., B. infantis, L. acidophilus and Enterococcus faecalis) [30]. In addition,
a synbiotic treatment, consisting of B. breve Yakult, L. casei Shirota and oligofructose-enriched inulin
(OF-IN), reduced urinary p-cresol, a proxy for colonic p-cresol generation, and promoted the growth of
bifidobacteria in healthy volunteers [84]. This is in line with the SYNERGY trial, showing elevated
levels of bifidobacteria in CKD stage 4 and stage 5 patients after intake of a synbiotic containing
galactooligosaccharides (GOS), OF, Bifidobacterium spp., Lactobacillus spp. and Streptococcus spp. [41].
Moreover, in the same study, excluding the patients receiving antibiotic treatments, the relative
abundance levels of F. prausnitzii increased and serum pCS levels decreased in the patients with
CKD [41]. Another study assessed the stimulation of saccharolytic fermentation and the reduction of
proteolytic fermentation attributed by the combination of L. casei Shirota and OF-IN [47]. Elevation
of SCFA-generating bacteria through high total dietary fiber intake may contribute to the reduction
of microinflammation present in CKD, and could hamper the progression of CKD [72,86]. In HD
patients, plasma pCS levels could be reduced by consumption of the prebiotic OF-IN [42] and intake of
the synbiotic containing L. casei Shirota, B. breve, GOS, lactose and monosaccharide [44]. Moreover,
the synbiotic Probinul-neutro® (CadiGroup, Rome, Italy) reduced plasma pCS levels in CKD stage 3
and stage 4 [45], while levels of IxS could be reduced by resistant starch [46] and by B. longum [43]
in HD patients. These studies indicate promising therapeutic interventions to reduce fecal p-cresol
and plasma pCS and IxS levels in CKD. Moreover, even in earlier CKD stages, already associated with
a change in the gut microbial composition [87], which might delay the progression of the disease.
In a recent paper by our group [34], regarding the same study population, the protein intake was
estimated by calculating the ratio of urinary urea over urinary creatinine, a proxy for protein intake.
This ratio was not significantly different among the different stages of CKD nor in comparison to the
control group and therefore we cannot attribute the observed changes in gut bacterial composition to
differences in protein intake in this study population.
A possible shortcoming of this study was the assessment of the gut microbial community by only
qPCR, depending on a selection of gut bacterial taxa, and not of the entire microbial community by
means of high-throughput molecular techniques. However, our qPCR assays indicate an alteration in
the gut microbial composition over the different stages of CKD and controls for nine bacterial taxa, of
which some are at species level. However, in a previous microbiome study by our research group,
the gut microbial composition of the HD patients from the current CKD cohort was analyzed with
phylogenetic community profiling and revealed a similar microbial profile, based on genera and higher
taxonomic taxa, was observed with that of controls [58]. This was in line with another sequencing study
comparing ESKD patients with controls [29], but not in a study comparing controls with non-dialyzed
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and dialyzed CKD patients [61,88]. The sequencing results of the CKD group are in preparation for
another paper, in view of the extent of the data.
In summary, isolation and quantification of PBUT precursor-generating bacteria from fecal samples
of patients with CKD (stages 1 and 5) showed that phenolic compounds are mostly generated by
anaerobic bacteria whereas indolic compounds are produced by both anaerobes and aerobes. The
present study is one of the first investigating PBUT precursor-generating bacterial concentrations with
qPCR in all stages of CKD, and indicated that kidney function decline is accompanied by a decrease in
the abundance of SCFA-generating bacteria, Bifidobacterium spp. and Streptococcus spp., and an increase
of aerobic bacteria, i.e., Enterobacteriaceae and E. coli. Our findings might trigger the development of
potential interventions to minimize the generation of especially p-cresol by the gut microbiota and
subsequently to reduce plasma pCS levels in patients with CKD. Moreover, in the future, these bacterial
species with the capacity to generate PBUT precursor metabolites need to be assessed in in vitro models
and in vivo studies to elucidate their pathophysiological role, e.g., their effect on the intestinal barrier
function and inflammation, in CKD.
4. Materials and Methods
4.1. Study Population and Sample Collection
The study population, from which a fecal sample was collected, has been previously used and
described, including the clinical parameters, by the authors [34]. Briefly, in total, 14 healthy controls, 111
non-dialyzed CKD patients (stages 1–5), 16 HD patients, and 11 PD patients were included. Exclusion
criteria were active infection (C-reactive protein, CRP > 20mg/L), immunosuppressive therapy, obesity
(Body Mass Index > 35), inflammatory bowel disease, active malignancy, cardiovascular event in the
past three months, pregnancy, transplantation, use of non-steroidal anti-inflammatory drugs within the
past month, vascular access problems for HD patients, and age < 18 years. Before inclusion, all patients
and healthy controls gave written informed consent. The study was conducted in accordance with
the Declaration of Helsinki, and approved by the Medial Ethics Committee of the Ghent University
Hospital (Ref 2010/033, B67020107926 and Ref 2012/603, B670201214999).
4.2. Culture Media
Prior to the isolation of PBUT precursor-generating bacteria, appropriate culture media were
selected. For this purpose, a total of 28 different culture broths (Figure S1) were compared with respect
to their ability to support growth of a test panel, composed of bacterial species known to generate
p-cresol and/or indole. AAA (total concentration of 2.5 mM l-tyrosine, 2.5 mM l-phenylalanine and
2.5 mM l-tryptophan, Sigma Aldrich, Saint Louis, MO, USA) were added to stimulate the growth
of proteolytic (fermentation) bacteria. Moreover, to mimic the natural gut environment of the fecal
bacteria, a sterile FS was prepared and added to some of the media. For this, whole fresh fecal
samples (n = 13; 29 g to 173 g) from healthy controls were mixed with a same fecal weight volume
of PBS (Phosphate buffered saline, Lonza, Basel, Switzerland) using a vortex. The fecal suspension
was centrifuged at 10,000× g for 30 min and the supernatant was centrifuged again at 30,000× g for
15 min. The supernatant was stored at −80 ◦C after vacuum filtration with a 0.22 µm filter (Steritop
threaded bottle top filter, Merck Chemicals, Brussels, Belgium) to remove viable bacteria. The different
media tested are summarized in Table S3. The bacterial test panel included Bacteroides fragilis (LMG
10263T), B. thetaiotaomicron (LMG 11262), Bifidobacterium adolescentis (LMG 10502T), B. bifidum (LMG
11041T), B. longum (LMG 13197T), Clostridioides difficile (LMG 21717T); Clostridium sporogenes (LMG
8421T t1), Lactobacillus acidophilus (CHCC 3777), L. paracasei (LAB109cas), Paraclostridium bifermentans
(LMG 3029), Escherichia coli (LMG 2092T) and Staphylococcus epidermidis (U9108901). Growth of the
bacterial test panel in the broth media was determined spectrophotometrically at 600 nm (Glomax®
Explorer Multimode Microplate Reader, Promega, Madison, Wisconsin) and growth was also confirmed
inoculating the broth onto SCH agar plates.
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Furthermore, to select the culture media that enabled maximal recovery of different fecal bacteria,
three fecal samples, from three controls, were cultured on five selected media, i.e., the only ones out of
28 combinations that supported growth of all species of the test panel. For this purpose, 1 g of each of
the samples was homogenized and 0.5 g of the homogenate was used to make a tenfold serial dilution,
using maximum recovery diluent solution (MRD, Sigma Aldrich). Fecal dilutions of 10-2 to 10-4 were
used to inoculate agar plates for aerobic incubation (2 days at 37 ◦C), and fecal dilutions of 10-4 to 10-6
for anaerobic incubation (7 days at 37 ◦C) (Figure S2). The colony forming units (CFU) on each agar
plate were counted and identified.
4.3. Isolation of Protein-Bound Uremic Toxin Precursor-Generating Bacteria from CKD Fecal Samples
Fecal samples were randomly selected from CKD 1 (n = 6) and CKD 5 (n = 6) patients and
used to culture in vitro PBUT precursor-generating bacteria. First, a tenfold serial dilution of each
fecal sample was prepared, with MRD as diluent solution. Fecal dilutions of 10−2 to 10−4 were used
for aerobic incubation (2 days at 37 ◦C), and fecal dilutions of 10−4 to 10−6 for anaerobic incubation
(6 days at 37 ◦C) were inoculated on YCFAG ∆0 +AAA +FS, SCH and 1203a media (CM0957 Anaerobe
Basal Broth, Oxoid, Thermo Fisher Scientific, Merelbeke, Belgium), of which the last medium was
recommended by the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) to
culture Akkermansia muciniphila.
4.4. Identification of Fecal Protein-Bound Uremic Toxin Precursor-Generating Bacteria
Direct identification of bacterial colonies was performed with a matrix assisted laser
desorption/ionization time-of-flight analyzer (MALDI-TOF, Bruker, Mannheim, Germany). For
MALDI-TOF identification, the bacterial colonies were spotted on a MALDI-TOF plate and 1 µL of
Bruker HCCA matrix solution (For 250 mL: 2.5 ± 0.3 mg α-Cyano-4-hydroxycinnamic acid, 125 mL
acetonitrile, 118.75 mL water, and 6.25 mL trifluoroacetic acid) was added. In case of no identification
with MALDI-TOF, 16S rRNA gene sequencing was performed by GATC (Eurofins Genomics, Ebersberg,
Germany).
4.5. Quantification of p-Cresol, Phenol, Indole and Indole-3-Acetic Acid in Broth Media
The concentrations of p-cresol (108 Da) and indole (117 Da) in the broth medium were measured
with reversed-phase HPLC. Chromatographic HPLC separation was performed at 26 ◦C on a
reversed-phase XBridge C8 column (3.5 µm, 150× 4.6 mm, Waters, Zellik, Belgium) with an Ultrasphere
5 ODS Guard column (5 µm, 45 × 4.6 mm, Hichrom, Reading, UK). The mobile phase consisted of
50 mM ammonium formate buffer (mobile phase A, pH 3.0) and methanol (mobile phase B). The
chromatographic separation consisted of a linear gradient at a flow of 1 mL/min, starting with 100% A
during the first 3 min, followed by a change into 100% B during the next 36 min. The latter composition
was held for 3 min and followed by a re-equilibration step. Fecal suspensions were filtered before
chromatography through an Amicon Ultra 0.5 mL filter (molecular weight cut-off 30 kDa, Millipore
Merck, Darmstadt, Germany). p-Cresol (λex: 278 nm, λem: 304 nm), and indole (λex: 275 nm, λem:
334 nm) were detected by a Waters 2475 fluorescence detector.
Concentrations of phenol (94 Da) and IAA (175 Da) were measured with reversed-phase UPLC
analysis. For the quantification of the total concentration of IAA, samples were deproteinized by heat
denaturation, followed by a filtration step through an Amicon Ultra 0.5 mL filter prior to reversed-phase
UPLC analysis [89]. Chromatographic UPLC separation was performed at 26 ◦C on a Waters Acquity
UPLC BEH C18 Van Guard column (1.7 µm, 100 x 2.1 mm). The mobile phase consisted of 50 mM
ammonium formate buffer (mobile phase A, pH 3.0) and methanol (mobile phase B). A linear gradient
elution was used to separate the compounds at a flow rate of 0.3 mL/min, and started at 98% A,
followed by a composition change to 90% A in 7 min. In the next 9 min, the mobile phase changed to
100% B and was held for 3 min. Finally, a re-equilibration step was performed. Phenol (λex: 275 nm,
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λem: 350 nm) and IAA (λex: 280 nm, λem: 350 nm) were detected by an Agilent G1316C fluorescence
detector (Agilent, Diegem, Belgium).
4.6. Quantification of Bacterial Species in Fecal Samples
To perform qPCR assays, bacterial DNA was extracted from fecal samples using the
PowerMicrobiome RNA isolation kit (Qiagen, Hilden, Germany) with the following modifications: the
DNase steps (steps 12 to 16) were not performed, in order to extract DNA next to RNA. Furthermore,
an additional heating step of 95 ◦C for 10 min after step 4 was added, to increase the DNA yield [90,91].
In addition to the total bacterial number also the abundance of 11 bacterial taxa in different
stages of CKD and controls was assessed. Of these, Bacteroides spp., Bifidobacterium spp., C. difficile,
Enterobacteriaceae, E. coli, F. prausnitzii, Roseburia spp., and Streptococcus spp. were selected based on their
PBUT precursor-generating capacity, observed in the present study and in in vitro studies [9]. Moreover,
A. muciniphila, Bacteroides spp., F. prausnitzii, Lactobacillus spp., Roseburia spp., and Streptococcus spp.
belonged to the top 10 bacterial taxa with the largest differences in proportions between HD patients
with high pCS/low IxS versus low pCS/high IxS serum levels, shown in a previous study of our
group [58], for which reason these were included here. Finally, the abundance of a well-known
SCFA-generator Butyricicoccus spp. [71] was also assessed.
To quantify the bacterial taxa from fecal samples, family-, genus- and species-specific qPCRs
were developed and performed on the basis of previously described formats [71,91–103]. Primers
and probes used are summarized in Table S4. The specificity of primers and probes was evaluated in
silico using Nucleotide BLAST (basic local alignment search tool). Primer sequences and the amplicon
sequence were further evaluated with the programs “OligoAnalyzer”, “mfold” and “DINAMelt” for
homo- and hetero-dimers, sequence length, GC percentage, and melting temperature. All primers
and the probe were purchased from Kaneka Eurogentec (Seraing, Belgium). To validate the specificity
of the amplification of the primers and probes, qPCR amplification was performed using template
DNA from different bacterial species (Table S5), with the LightCycler480 (LC480, Roche Life Science,
Vilvoorde, Belgium). Table S4 summarizes the qPCR mixes and thermal cycling conditions for each
qPCR. To verify the specificity of the qPCRs without the usage of a probe, melting curve analysis was
performed. Of every qPCR, the limit of quantification (LOQ) and LOD was determined, as described
by Forootan et al. [104] (Table S4). For all qPCR reactions, every sample was amplified in duplicate,
standard dilution series were used as positive controls, and qPCR mixes without DNA were included
as negative controls. Standard tenfold dilution series were prepared from DNA extracts indicated in
Table S5.
4.7. Statistical Analysis
All statistical analyses were performed by IBM SPSS Statistics for Windows, version 26 (IBM,
Armonk, NY, USA) and graphs were made with R (2019, version 3.6.0). Prior to statistical analysis of
the qPCR concentration results of the bacterial species, the data were log10 transformed. To determine
the normality of the data, a Shapiro-Wilk test was performed. Depending on the distribution, the
data are presented as mean ± standard deviation or median (25th–75th percentile). To compare the
characteristics and the bacterial concentrations between the different stages of CKD (control, CKD stage
1–5, HD and PD), an ANOVA or a Kruskal-Wallis test, both with a Benjamini-Hochberg correction for
multiple testing, was performed according the data distribution. Correlations between the abundance
of the bacterial taxa and different study groups (control and CKD 1-5) or eGFR, were performed with
the Spearman’s rank test (rs). Differences were considered as statistically significant when the p-value
was below 0.05.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/6/1986/
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